MiniMed Group Expands Board, Appoints Alcon CEO and Medtronic SVP as New Directors
MMED sits 33% above its 52-week low of $10.65 on elevated volume (6.6× avg).
Summary
MiniMed Group expanded its board from nine to eleven members, appointing David Endicott, CEO of Alcon, and Linnea Burman, SVP at Medtronic, as new independent directors.
Key Events · Executive and Board Changes · MMED
-
Board Expansion
The Board of Directors increased its size from nine to eleven members, creating two new vacancies.
-
New Director Appointment (David Endicott)
David Endicott, currently the Chief Executive Officer of Alcon, Inc., was appointed as a Class I independent director and will serve on the Compensation and Talent Committee.
-
New Director Appointment (Linnea Burman)
Linnea Burman, Senior Vice President & President, Neurovascular at Medtronic plc, was appointed as a Class II director. She will not receive compensation for her service as long as Medtronic is an affiliate of MiniMed.
-
Annual Meeting Scheduled
The 2026 annual meeting of stockholders is scheduled for Friday, October 9, 2026, with specific deadlines for stockholder proposals and director nominations.
Analysis · MMED · Industrial Applications And Services
MiniMed Group has strengthened its Board of Directors by expanding its size and appointing two highly experienced executives. David Endicott, CEO of Alcon, Inc., brings significant leadership from the eye care industry, while Linnea Burman, a Senior Vice President at Medtronic plc, adds deep expertise from the medical technology sector. These appointments enhance the board's strategic capabilities and industry connections.
At the time of this filing, MMED was trading at $14.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4B. The 52-week trading range was $10.65 to $19.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.